1TZ Stock Overview
Through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
InfuSystem Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.65 |
| 52 Week High | US$9.75 |
| 52 Week Low | US$5.15 |
| Beta | 1.45 |
| 11 Month Change | 44.17% |
| 3 Month Change | 50.43% |
| 1 Year Change | -3.89% |
| 33 Year Change | -42.33% |
| 5 Year Change | n/a |
| Change since IPO | -52.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1TZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 3.6% | 1.8% | 0.8% |
| 1Y | -3.9% | 17.4% | 9.1% |
Return vs Industry: 1TZ underperformed the German Healthcare industry which returned 17.4% over the past year.
Return vs Market: 1TZ underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 1TZ volatility | |
|---|---|
| 1TZ Average Weekly Movement | 8.6% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1TZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1TZ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 508 | Rich DiIorio | www.infusystem.com |
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
InfuSystem Holdings, Inc. Fundamentals Summary
| 1TZ fundamental statistics | |
|---|---|
| Market cap | €187.74m |
| Earnings (TTM) | €1.42m |
| Revenue (TTM) | €126.74m |
128.2x
P/E Ratio1.4x
P/S RatioIs 1TZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1TZ income statement (TTM) | |
|---|---|
| Revenue | US$132.78m |
| Cost of Revenue | US$63.89m |
| Gross Profit | US$68.90m |
| Other Expenses | US$67.41m |
| Earnings | US$1.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.07 |
| Gross Margin | 51.89% |
| Net Profit Margin | 1.12% |
| Debt/Equity Ratio | 50.4% |
How did 1TZ perform over the long term?
See historical performance and comparison